Oxford Immunotec (OXFD) Gets Favorable Patent Infringement Verdict

October 3, 2016 4:03 PM EDT

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Oxford Immunotec Global PLC (Nasdaq: OXFD) announced that the U.S. District Court for the District of Massachusetts reinstated the kit claims of the Company’s patent infringement claims against the defendants, Qiagen, Inc., Quest Diagnostics Inc. and Laboratory Corporation of America Holdings, following its review of the Magistrate Judge’s Report and Recommendation of August 31, 2016. In issuing its ruling, the District Court rejected Qiagen’s arguments that the patents were not valid and permitted the case to proceed on Qiagen’s products and its customers’ use of them. As a result of the District Court’s decision, all claims of the Company's six patents remain at issue and the case will proceed to the next phases of discovery and, ultimately, trial.

“We are pleased by the court’s decision and, in particular, the reinstatement of the direct infringement claims against Qiagen,” said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. “Defense of all claims of our patents remains a priority for us and we will continue to pursue such defense vigorously.”

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Hot Corp. News, Litigation

Related Entities

Definitive Agreement

Add Your Comment